Compare ALG & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALG | VCEL |
|---|---|---|
| Founded | 1955 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1996 | 1996 |
| Metric | ALG | VCEL |
|---|---|---|
| Price | $177.43 | $35.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $225.00 | $58.50 |
| AVG Volume (30 Days) | 113.3K | ★ 711.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 8.59 | 0.32 |
| Revenue | ★ $1,603,715,000.00 | $276,259,000.00 |
| Revenue This Year | $5.26 | $19.10 |
| Revenue Next Year | $3.97 | $17.95 |
| P/E Ratio | ★ $20.55 | $107.75 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $156.30 | $28.95 |
| 52 Week High | $233.29 | $45.97 |
| Indicator | ALG | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 57.89 |
| Support Level | $168.24 | $34.61 |
| Resistance Level | $181.61 | $38.48 |
| Average True Range (ATR) | 4.99 | 1.53 |
| MACD | 2.24 | 0.44 |
| Stochastic Oscillator | 74.78 | 93.04 |
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Its products include agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck-mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, snow removal equipment, etc. The company's reportable segments are Vegetation Management, which generates the maximum revenue, and Industrial Equipment. Geographically, the company generates maximum revenue from the United States, followed by Canada, France, the UK, Brazil, the Netherlands, and other regions.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.